New affiliated members ADITEC aims to produce new knowledge for the next generation of new human vaccines. This goal requires a multidisciplinary approach where diverse and complementary scientific disciplines and technologies converge. Besides the interaction between the current 42 full […]
Partners of the ADITEC consortium are presenting the third course on adjuvants and vaccine formulation. Dates: 9-13 February 2015 Location: Vaccine Formulation Laboratory at University of Lausanne, Switzerland Topics: Formulation and characterization of Aluminum salts, Water-in-Oil emulsions, Oil-in-Water emulsions, and […]
Support for Vaccine Development Deadline: 30 May 2014 5:00 p.m. CET Anticipated Decision Date 30 June 2014 Please forward this message to anyone who could be interested. The High Impact project on Advanced Immunization Technologies (ADITEC), funded through the 7th […]
Happy New Year The ADITEC project team wishes all partners, collaborators and those who are interested in our work, a very Happy New year! In 2014 we will continue developing advanced immunization technologies in order to improve health for humanity. […]
ADITEC’s second year progress The high impact project Advanced Immunization Technologies (ADITEC) started as an ambitious €30 million EU project to boost vaccine research. During the 5 year term of the project, the goal is to develop novel immunization technologies […]
The Institute for Biomedical Aging (IBA) was founded in 1992 as an institute of the Austrian Academy of Sciences and joined the University of Innsbruck in 2012. Worldwide, the segment of the population aged 60 or over is increasing rapidly. […]
Leiden University Medical Center (LUMC) is a medical centre of excellence that provides clinical inpatient and outpatient care, modern education, and innovative basic, translational and clinical research, pursuing excellence in each of these areas. The Department of Infectious Diseases at […]
Support for Vaccine Development Deadline: 30 May 2013 5:00 p.m. CEST Anticipated Decision Date 30 June 2013 Please forward this message to anyone who could be interested. The High Impact project on Advanced Immunization Technologies (ADITEC), funded through the 7th […]
ADITEC’s first year progress The high impact project Advanced Immunization Technologies (ADITEC) started as an ambitious €30 million EU project to boost vaccine research. During the 5 year term of the project, the goal is to develop novel immunization technologies […]
Adjuvanted trivalent influenza vaccine: a randomised controlled trial to determine the kinetics of the functional genomic response in young children. In the 2012 influenza season, ADITEC partners (University of Geneva, University of Oxford, Emory University Atlanta and Novartis) conducted a […]